Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes

被引：0
|
作者：
Al Ali, Najla [1 ]
Sallman, David [1 ]
Chan, Onyee [1 ]
Padron, Eric [1 ]
Sweet, Kendra [1 ]
Kuykendall, Andrew [1 ]
Lancet, Jeffrey [1 ]
Komrokji, Rami [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
MDS; azacitidine; venetoclax;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-128
引用
收藏
页码：S341 / S341
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
    Garcia, Jacqueline S.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Fleming, Shaun
    Fong, Chun Yew
    Cook, Rachel
    Jacoby, Meagan
    Nowak, Daniel
    Chyla, Brenda
    Zhou, Ying
    Ku, Grace
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2023, 142
  • [2] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    Dinmohamed, A. G.
    van Norden, Y.
    van de Loosdrecht, A. A.
    Jongen-Lavrencic, M.
    [J]. LEUKEMIA, 2016, 30 (08) : 1795 - +
  • [3] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    A G Dinmohamed
    Y van Norden
    A A van de Loosdrecht
    M Jongen-Lavrencic
    [J]. Leukemia, 2016, 30 : 1795 - 1796
  • [4] Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naive higher-risk myelodysplastic syndromes.
    Fong, Chun Yew
    Wei, Andrew H.
    Frattini, Mark G.
    Jacoby, Meagan
    Borate, Uma
    Gotze, Katharina S.
    Garcia, Jacqueline Suen
    Pollyea, Daniel Aaron
    Holes, Leanne
    Zhou, Ying
    Fakouhi, Kaffa Mussumeh
    Leverson, Joel
    Harb, Jason G.
    Agarwal, Suresh K.
    Attarchi, Faraneh
    Mabry, Mack H.
    Hong, Wan-Jen
    Jahn, Thomas Michael
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Ganetsky, Rebecca
    Latham, Deborah
    Paulic, Katarina
    Afable, Manuel
    Saba, Hussain I.
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2253 - 2258
  • [6] Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes
    Levy, A. R.
    Zou, D.
    Risebrough, N.
    Buckstein, R.
    Kim, T.
    Brereton, N.
    [J]. CURRENT ONCOLOGY, 2014, 21 (01) : E29 - E40
  • [7] Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Tiu, Ramon V.
    Komrokji, Rami
    Lancet, Jeffrey
    Advani, Anjali S.
    Afable, Manuel
    Englehaupt, Ricki
    Juersivich, Joyce
    Cuthbertson, David
    Paleveda, Jennifer
    Tabarroki, Ali
    Visconte, Valeria
    Makishima, Hideki
    Jerez, Andres
    Paquette, Ronald
    List, Alan F.
    Maciejewski, Jaroslaw P.
    [J]. BLOOD, 2012, 120 (25) : 4945 - 4951
  • [8] Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results
    Wei, Andrew H.
    Garcia, Jacqueline S.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nowak, Daniel
    Peterlin, Pierre
    Jurcic, Joseph
    Jacoby, Meagan A.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Cunningham, Ilona
    Zhou, Ying
    Hoffman, David
    Hogdal, Leah
    Naqvi, Kiran
    Kye, Steve
    Garcia-Manero, Guillermo
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S343
  • [9] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors’ reply
    T Bernal
    P Martínez-Camblor
    J Sánchez-García
    G Sanz
    [J]. Leukemia, 2016, 30 : 740 - 741
  • [10] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply
    Bernal, T.
    Martinez-Camblor, P.
    Sanchez-Garcia, J.
    Sanz, G.
    [J]. LEUKEMIA, 2016, 30 (03) : 740 - 741
12345